In a comparison of matched primary and distant metastatic HER2+ breast cancers (soft tissue, lung, brain), Schlam et al. showed that primary sites had higher tumour infiltration, increased expression of immune activation markers compared to secondary sites [27]. This evidence concerns the gene ERBB2 and breast carcinoma.